Abbott partners with Novo Nordisk India to launch Extensior, broadening access to Semaglutide (Ozempic) for advanced diabetes management.
ABBOTINDIA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.0 pts more than Nifty Midcap 150 and 3.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Abbott India has announced a strategic collaboration with Novo Nordisk India to commercialize Extensior®, a second brand of the blockbuster diabetes drug Ozempic® (semaglutide), in India. Under the agreement, Novo Nordisk will develop and manufacture the drug while Abbott will handle commercialization, leveraging its strong distribution network to expand access beyond regions Novo Nordisk currently serves. Extensior® is a once-weekly GLP-1 receptor agonist injection offered in a FlexTouch® pen (0.25mg, 0.5mg, 1mg doses) that delivers HbA1c reduction, weight-loss benefits, and lowers risk of cardiovascular and kidney events. The product is approved as an adjunct to diet and exercise for adults with type 2 diabetes and will join Abbott's expanding diabetes portfolio. The launch targets India's massive diabetes burden of over 100 million patients, projected to reach 150 million by 2050, where 43% remain undiagnosed and diabetes-related spending already exceeds USD 9.8 billion.
This marquee partnership strengthens Abbott India's diabetes franchise and positions it to capture a meaningful share of India's fast-growing GLP-1 market. While near-term financial impact is modest given the early-stage launch, the deal could become a long-term revenue driver as semaglutide penetration scales in India.